Novo Nordisk links CagriSema to 25% weight loss in women
The figure comes from a new company analysis breaking out results for female participants rather than the overall trial population.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 20 09:23 ETSource: Quartz
The wire
- 01Novo Nordisk said a new analysis associated its cagrilintide-semaglutide combination CagriSema with 25% weight loss in women.
- 02CagriSema pairs an amylin analog with semaglutide, and sex-specific response data would shape how prescribers set expectations for the combination.
- 03The number comes from a company analysis of its own trial data rather than a separately powered study, and subgroup results carry the usual caveats.
From the source
Read at qz.comNovo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
